Cash Flow And ProfitabilityCytek reiterated their expectations for FY24 positive cash flow from operations as they march towards consistent profitability.
Market RecoveryManagement highlighted positive early signs of recovery in the US instrument market, which negatively impacted Q2 results, accredited to biotech market improvement.
Product PerformanceAPAC and EMEA end markets are performing well, and new products should also help keep this outperformance consistent.